Atrium Innovations Announces 2011 Second Quarter Financial Results
Strong Contribution from Acquisitions coupled
with Solid Organic Growth
QUEBEC CITY, Aug. 10, 2011 /PRNewswire/ - Atrium Innovations Inc. (TSX: ATB), a globally recognized leader in the development, manufacturing, and commercialization of innovative, science-based dietary supplements endorsed by health professionals, today released its 2011 second quarter results for the period ended June 30, 2011.
Second Quarter Highlights:
(All amounts are in US dollars.)
- Revenue growth of 23.5% over previous year to reach $105.2 million
- Strong contribution of Seroyal acquisition with integration substantially completed
- Branded organic growth reached 6.0%
- EBITDA of $23.8 million or 22.6% of revenues, an increase of 17.2% compared to last year
- Diluted EPS of $0.44 for the quarter
- Cash flow before working capital was up 24.3% to $18.9 million.
- Subsequent to quarter-end, closing a CAN$100 million of convertible debentures
"We are pleased with our second quarter results. We substantially completed the integration of Seroyal, and the new North American management structure implemented a few months ago is beginning to provide tangible benefits to support our next growth phase," said Pierre Fitzgibbon, President and Chief Executive Officer.
"We experienced strong revenue growth from acquisitions, as well as solid global organic growth for a second consecutive quarter from our branded products. Moreover, we increased our EBITDA margin compared to the first quarter of 2011, and we should expect further improvements going forward with the various initiatives underway in our global supply chain management program".
"We are confident in our ability to out-perform the industry since we have started several new organic growth initiatives," concluded Mr. Fitzgibbon.
For the quarter ended June 30, 2011, Atrium recorded revenues of $105.2 million representing an increase of 23.5% compared to revenues of $85.2 million in 2010. This increase is mainly attributable to the acquisitions of Seroyal and Minami as well as to organic growth of the Company's branded business.
EBITDA increased by 17.2% to $23.8 million or 22.6% of revenues compared to $20.3 million or 23.8% of revenues for the same period in 2010. The acquisitions of Seroyal and Minami and organic growth contributed to the increase in EBITDA.
Net earnings attributable to shareholders were $14.4 million in 2011 compared to $12.4 million in 2010, representing an increase of 16.1%. Net earnings per share ("EPS") on a diluted basis rose to $0.44 per share, as compared to $0.37 per share for the same period in 2010.
Cash flows from operating activities before changes in non-cash working capital items were $18.9 million compared to $15.2 million in 2010. As at June 30, 2011, the Company had a total debt of $306.7 million and a cash position of $15.0 million. Subsequent to quarter-end, the Company announced yesterday the closing of a convertible debenture public offering of CAN$75 million and a concurrent private placement of CAN$25 million. The net proceeds will be used to reduce the Company's outstanding indebtedness.
"Cash flow before working capital of $18.9 million during the quarter increased 24.3% over the same period last year confirming our ability to generate strong cash flows," said Mario Paradis, Chief Financial Officer of the Company. "Since the beginning of 2011, we acquired over 200,000 shares under our normal course issuer bid program and we will continue to act on our program depending on the circumstances. We also are pleased with our recently completed $100 million convertible debenture deal. It represents an important milestone to manage our capital structure and further support our growth strategy," concluded Mr. Paradis.
About Atrium
Atrium Innovations Inc. is a globally recognized leader in the development, manufacturing, and commercialization of innovative, science-based natural health products endorsed by health professionals. The Company distributes its extensive portfolio of products mainly in the healthcare practitioner and health food and specialized store channels, with a primary focus in North America and Europe. Atrium is at the forefront of science, innovation and education in the dietary supplement industry. The Company has over 1,000 employees and operates seven manufacturing facilities. Additional information is available at www.atrium-innovations.com.
Conference Call and Webcast
Atrium will hold its quarterly conference call and webcast to discuss its 2011 second quarter results on Thursday August 11, 2011 at 8:30 a.m., Eastern Time. Participants may access the call by using the following numbers: 514-807-8791, 877-974-0445, or 416-644-3423. A live webcast is also available via the Company's website at www.atrium-innovations.com in the News Center section. A replay of the webcast will also be available on our website for a period of 30 days. A copy of Atrium's interim unaudited financial statements will also be available on the Company's website.
Caution Regarding Non-IFRS Financial Measures
The Company provides non-IFRS financial measures (gross profit*, EBIT*, and EBITDA*) as supplemental information regarding its operational performance. These non-IFRS financial measures are directly derived from the Company's financial statements and are presented in a consistent manner. The Company uses these measures for the purposes of evaluating its historical and prospective financial performance, as well as its performance relative to competitors. These measures also help the Company to plan and forecast for future periods as well as to make operational and strategic decisions. The Company believes that providing this information to investors, in addition to IFRS measures, allows them to see the Company's results through the eyes of management, and to better understand its historical and future financial performance.
The presentation of this additional information is not prepared in accordance with IFRS. Therefore, the information may not necessarily be comparable to that of other companies and should be considered as a supplement to, not a substitute for, or superior to, the comparable measures calculated in accordance with IFRS.
* Gross profit means sales less cost of sales. EBIT means earnings before interest and tax. EBITDA means earnings before interest, tax, depreciation, amortization and acquisitions costs.
Cautionary Note and Forward-Looking Statements
This press release contains certain forward-looking statements with respect to the Company. These forward-looking statements, by their nature, require the Company to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements. Forward-looking statements are not guarantees of performance. These forward-looking statements, including financial outlooks, may involve, but are not limited to, comments with respect to the Company's business or financial objectives, its strategies or future actions, its targets, expectations for financial condition or outlook for operations and future contingent payments. Words such as "may", "will", "would", "could", "expect", "believe", "plan", "anticipate", "intend", "estimate", "continue", or the negative or comparable terminology, as well as terms usually used in the future and the conditional, are intended to identify forward-looking statements. Information contained in forward-looking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including management's perceptions of historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. The Company considers these assumptions to be reasonable based on information currently available to it, but cautions the reader that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company and its business.
For additional information with respect to these and other factors and assumptions underlying the forward-looking statements made in this press release, see the Company's quarterly and annual Management Discussion and Analysis for the fiscal year ended December 31, 2010 filed with the Canadian securities commissions. The forward-looking information set forth herein reflects the Company's expectations as at the date of this press release and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.
Attachments: | Financial summary Balance sheet, results and cash flow statement |
Atrium Innovations Inc.
Financial Summary (unaudited)
(in millions of US dollars except per share amounts)
Consolidated results for the quarters ended June 30,
(unaudited)
2011 $ |
2010 $ |
Change | ||||
Revenues | 105.2 | 85.2 | 23% | |||
Gross profit (1) | 54.9 | 48.9 | ||||
52.2% | 57.4% | |||||
EBITDA (2) | 23.8 | 20.3 | 17% | |||
22.6% | 23.8% | |||||
Net earnings attributable to shareholders | 14.4 | 12.4 | 17% | |||
Net earnings per share | ||||||
Basic | 0.44 | 0.38 | ||||
Diluted | 0.44 | 0.37 | ||||
Reconciliation to non IFRS Financial Data | ||||||
Net earnings attributable to shareholders |
14.4 |
12.4 |
||||
Acquisition-related costs and interest expenses for acquisition-related contingent liabilities (after-tax) |
- | 0.1 | ||||
Net earnings | 14.4 | 12.5 | ||||
Net diluted earnings per share | 0.44 | 0.38 |
(1) Gross profit means sales less cost of goods sold.
(2) EBITDA means earnings before interest, taxes, depreciation, amortization and acquisition related costs.
Atrium Innovations Inc.
Financial Summary (unaudited)
(in millions of US dollars except per share amounts)
Consolidated results for the six-month period ended June 30,
(unaudited)
2011 $ |
2010 $ |
Change | ||||
Revenues | 212.9 | 175.2 | 22% | |||
Gross profit (1) | 115.7 | 100.4 | ||||
54.3% | 57.3% | |||||
EBITDA (2) | 47.2 | 41.5 | 14% | |||
22.2% | 23.7% | |||||
Net earnings attributable to shareholders | 28.6 | 24.8 | 15% | |||
Net earnings per share | ||||||
Basic | 0.87 | 0.76 | ||||
Diluted | 0.86 | 0.75 | ||||
Reconciliation to non IFRS Financial Data | ||||||
Net earnings attributable to shareholders | 28.6 | 24.8 | ||||
Acquisition-related costs and interest expenses for acquisition-related contingent liabilities (after-tax) |
0.1 | 0.7 | ||||
Net earnings | 28.7 | 25.5 | ||||
Net diluted earnings per share | 0.86 | 0.77 |
(1) Gross profit means sales less cost of goods sold.
(2) EBITDA means earnings before interest, taxes, depreciation, amortization and acquisition related costs.
Atrium Innovations Inc.
Consolidated Balance Sheets
(Expressed in thousands of US dollars)
As at June 30, | As at December 31, | ||
2011 $ |
2010 $ |
||
Assets | |||
Current assets | |||
Cash | 15,043 | 12,049 | |
Accounts receivable | 55,025 | 50,070 | |
Income taxes recoverable | 6,342 | 5,018 | |
Inventory | 84,117 | 79,243 | |
Prepaid expenses | 5,411 | 4,384 | |
165,938 | 150,764 | ||
Property, plant and equipment | 22,219 | 21,916 | |
Deferred charges and others | 3,627 | 3,238 | |
Intangible assets | 267,745 | 251,939 | |
Goodwill | 375,876 | 360,963 | |
Deferred tax assets | 5,155 | 8,564 | |
840,560 | 797,384 | ||
Liabilities | |||
Current liabilities | |||
Accounts payable and accrued liabilities | 39,181 | 38,564 | |
Provisions | 2,106 | 3,351 | |
Contingent considerations | 15,194 | 17,583 | |
Income taxes | 598 | 1,148 | |
Deferred revenues | 344 | 944 | |
Derivative financial instruments | 959 | - | |
Current portion of long-term debt | 291 | 217 | |
58,673 | 61,807 | ||
Long-term debt | 306,429 | 275,614 | |
Deferred tax liabilities | 69,278 | 68,970 | |
Contingent considerations | - | 11,877 | |
Deferred revenues | 152 | 218 | |
Derivative financial instruments | - | 2,256 | |
434,532 | 420,742 | ||
Shareholders' Equity | |||
Share capital | 92,466 | 92,664 | |
Stock options reserve | 2,028 | 1,767 | |
Retained earnings | 314,490 | 288,607 | |
Accumulated other comprehensive income | (3,679) | (6,576) | |
405,305 | 376,462 | ||
Non-controlling interest | 723 | 180 | |
406,028 | 376,642 | ||
840,560 | 797,384 |
Atrium Innovations Inc.
Consolidated Statements of Earnings
(tabular amounts in thousands of US dollars, except share and per share data)
Quarters ended June 30, | Six months ended June 30, | ||||||
2011 $ |
2010 $ |
2011 $ |
2010 $ |
||||
Revenues | 105,161 | 85,183 | 212,913 | 175,236 | |||
Operating expenses | |||||||
Cost of sales | 50,272 | 36,332 | 97,227 | 74,788 | |||
Selling and administrative expenses | 32,185 | 29,825 | 70,780 | 61,733 | |||
Research and development costs | 566 | 505 | 1,135 | 1,063 | |||
83,023 | 66,662 | 169,142 | 137,584 | ||||
Earnings from operations | 22,138 | 18,521 | 43,771 | 37,652 | |||
Other revenues (expenses) | |||||||
Financial revenues | 69 | 40 | 115 | 261 | |||
Financial expenses | (2,744) | (1,773) | (4,743) | (3,537) | |||
Foreign exchange gain (loss) | (45) | 704 | (242) | 659 | |||
(2,720) | (1,029) | (4,870) | (2,617) | ||||
Earnings before the following items | 19,418 | 17,492 | 38,901 | 35,035 | |||
Income tax expense | 4,728 | 5,131 | 9,797 | 10,244 | |||
Net earnings for the period | 14,690 | 12,361 | 29,104 | 24,791 | |||
Net earnings for the period attributable to | |||||||
Shareholders | 14,446 | 12,361 | 28,561 | 24,791 | |||
Non-controlling interest | 244 | - | 543 | - | |||
Net earnings per share | |||||||
Basic | 0.44 | 0.38 | 0.87 | 0.76 | |||
Diluted | 0.44 | 0.37 | 0.86 | 0.75 | |||
Weighted average number of shares outstanding (000's) |
|||||||
Basic | 32,723 | 32,667 | 32,749 | 32,667 | |||
Diluted | 33,107 | 33,197 | 33,157 | 33,203 |
Atrium Innovations Inc.
Consolidated Statements of Cash Flows
(expressed in thousands of US dollars)
Quarters ended June 30, | Six months ended June 30, | |||||||
2011 $ |
2010 $ |
2011 $ |
2010 $ |
|||||
Cash flows from operating activities | ||||||||
Net earnings for the period | 14,690 | 12,361 | 29,104 | 24,791 | ||||
Adjustments for: | ||||||||
Depreciation and amortization | 1,647 | 1,761 | 3,385 | 3,189 | ||||
Deferred charges | 212 | (247) | 259 | (70) | ||||
Deferred revenues | (379) | (346) | (698) | (619) | ||||
Stock-based compensation costs | 199 | 74 | 288 | 145 | ||||
Interest expense | 2,447 | 1,487 | 4,058 | 2,963 | ||||
Deferred income taxes | 71 | 149 | 1,340 | 67 | ||||
Change in non-cash operating working capital items | 1,748 | (4,865) | (11,607) | (19,695) | ||||
Cash flows from operating activities | 20,635 | 10,374 | 26,129 | 10,771 | ||||
Cash flows from financing activities | ||||||||
Increase in long-term debt | 187 | 1,434 | 232,898 | 25,947 | ||||
Payments on long-term debt | (12,699) | (8,188) | (225,602) | (9,558) | ||||
Deferred financing costs | (239) | (36) | (428) | (69) | ||||
Issuance of shares | 159 | - | 347 | 48 | ||||
Redeemed and cancelled under a normal course issuer bid | (1,661) | - | (3,250) | - | ||||
Interest paid | (2,011) | (1,149) | (3,218) | (2,568) | ||||
Cash flows from financing activities | (16,264) | (7,939) | 747 | 13,800 | ||||
Cash flows from investing activities | ||||||||
Business acquisitions, net of cash acquired | (3,642) | (341) | (16,265) | (27,637) | ||||
Purchase of property, plant and equipment | (1,238) | (885) | (1,697) | (1,681) | ||||
Acquisition of intangible assets | (2,930) | (94) | (5,031) | (251) | ||||
Cash flows from investing activities | (7,810) | (1,320) | (22,993) | (29,569) | ||||
Net change in cash | (3,439) | 1,115 | 3,883 | (4,998) | ||||
Effect of exchange rate changes on cash | 184 | (641) | (889) | (1,173) | ||||
Increase (decrease) in cash | (3,255) | 474 | 2,994 | (6,171) | ||||
Cash - Beginning balance | 18,298 | 10,522 | 12,049 | 17,167 | ||||
Cash - Ending balance | 15,043 | 10,996 | 15,043 | 10,996 |
SOURCE ATRIUM INNOVATIONS INC.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article